918972-54-0

Basic information

• Product Name: Montelukast Styrene
• Synonyms: Montelukast Styrene;1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-Methylethenyl)phenyl]propyl]thio]Methyl];Montelukast EP IMpurity B;Montelukast Methylstyrene IMpurity;Cyclopropaneacetic acid, 1-[[[(1R)-1-[3-[(1E)-2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-Methylethenyl)phenyl] propyl]thio]Methyl]-;(R,E)-2-(1-(((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(prop-1-en-2-yl)phenyl)propyl)thio)methyl)cyclopropyl)acetic acid;Montelukast Methylstyrene;Montelukast Impurity B
• CAS NO: 918972-54-0
• Molecular Formula: C₃₅H₃₄ClNO₂S
• Molecular Weight: 568.16796
• Product Categories: Heterocycles;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 918972-54-0.mol

Chemical Properties

• Melting Point: 154-156°C
• Boiling Point: 729.234°C at 760 mmHg
• Flash Point: 394.827°C
• Appearance: /
• Density: 1.238g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.676
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 4.76±0.10(Predicted)
• CAS DataBase Reference: Montelukast Styrene(CAS DataBase Reference)
• NIST Chemistry Reference: Montelukast Styrene(918972-54-0)
• EPA Substance Registry System: Montelukast Styrene(918972-54-0)

Safety Data

• Hazardous Substances Data: 918972-54-0(Hazardous Substances Data)

Usage

Uses

Montelukast Styrene is primarily used as a reference standard for quality control and analytical testing in the pharmaceutical industry. It helps ensure the purity and safety of Montelukast medications by providing a benchmark for comparison during testing and analysis.
Used in Pharmaceutical Industry:
Montelukast Styrene is used as a reference standard for quality control and analytical testing to ensure the purity and safety of Montelukast medications. It serves as a benchmark for comparison during testing and analysis, helping to maintain the quality and efficacy of asthma and allergic rhinitis treatments.

InChI:InChI=1/C35H34ClNO2S/c1-24(2)31-9-4-3-7-26(31)13-17-33(40-23-35(18-19-35)22-34(38)39)28-8-5-6-25(20-28)10-15-30-16-12-27-11-14-29(36)21-32(27)37-30/h3-12,14-16,20-21,33H,1,13,17-19,22-23H2,2H3,(H,38,39)/b15-10+/t33-/m1/s1

Upstream product

• 158966-92-8 montelukast 
• 1197374-09-6 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propyl acetate 
• 1197374-10-9 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-isopropenylphenyl)propan-1-ol hydrochloride 
• 181139-72-0 methyl-[(E)]-2-[3(S)-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-hydroxypropyl] benzoate 
• 287930-77-2 (S,E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-ol 
• 149968-11-6 methyl 2-(3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-oxopropyl)benzoate 
• 1197414-05-3 C₂₉H₂₆ClNO 
• 869066-93-3 (S)-1-(3-((E)-2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl acetate 

Downstream Products

• 1266620-74-9 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(hydroxy-1-methylethyl)phenyl]propyl]-sulfonyl]methyl]-cyclopropane acetic acid 
• 855473-51-7 1-(((1(R)-(3-(2(E)-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid methyl ester 
• 1334676-80-0 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[(prop-1-en-2-yl)phenyl]propyl]thio]methyl]cyclopropane acetic acid methyl ester 
• 1351973-25-5 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-methoxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid 
• 1197374-06-3 montelukast 1-methyl-3-phenylpropyl amine salt 
• 1250477-73-6 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]-phenyl]-3-[(prop-1-en-2-yl)phenyl]propyl]sulfinyl]methyl]-cyclopropaneacetic acid 
• 1187586-61-3 [R, E]-[[1-[3-[2-(7-chloro-2-quinolinyl)-2-(S)-[(carboxymethyl)cyclopropyl]methyl]thio]ethyl]phenyl]-3-[[[[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid 
• 1187586-58-8 [R, E]-[[1-[3-[2-(7-chloro-2-quinolinyl)-2-(R)-[(carboxymethyl)cyclopropyl]methyl]thio]ethyl]phenyl]-3-[[[[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]-cyclopropane acetic acid 
• 909849-96-3 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]-phenyl]-3-[2-(-hydroxy-1-methylethyl) phenyl]propyl]-sulfinyl] methyl] cyclopropaneacetic acid 
• 151767-02-1 Montelukast sodium 
• 158966-92-8 montelukast 
• 1197374-12-1 [1-[(R)-1-(3-[(E)-2-(7-chloroquinolin-2-yl)vinyl]-phenyl)-3-(2-isopropenylphenyl)propylsulfanylmethyl]cyclopropyl]acetic acid dicyclohexylamine salt 
• 1351973-24-4 C₄₁H₄₄ClNO₄S₂ 
• 1351973-23-3 [R,E]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[(prop-1-en-2-yl)phenyl]-propyl]sulfonyl]methyl]cyclopropane acetic acid 

Relevant articles and documents

Identification, synthesis and characterization of impurities of Montelukast sodium

Montelukast sodium is a selective leukotriene receptor antagonist which inhibits cysteinyl leukotriene CysLT1 receptor. Various synthesis of Montelukast is published. During laboratory optimization and later in bulk synthesis formation of various impurities was detected. Besides, pharma Europa draft mention nine process related impurities. However, the method of preparation of most of these impurities is not available in literature. Also, different route of synthesis will have different impurity profile and those process related impurities are not covered in pharmacopeias. In this study we report the synthesis of possible process impurities, including seven impurities (A-H) mentioned in pharma Europa.

SPECIFIC IMPURITIES OF MONTELUKAST

The subject-matter of the invention consists in a method of removing specific impurities of montelukast of formula (I), which occur due to chemical instability of the target substance and also contaminate the substance in the preparation process. Further, methods of isolation of specific impurities of montelukast defined by formulae (V-A), (IV-A), (XIIIa-A), (XIIIb-A) and analytic methods used for the control of the production of montelukast in the pharmaceutical quality.

PROCESS FOR PREPARING MONTELUKAST SODIUM CONTAINING CONTROLLED LEVELS OF IMPURITIES

The present invention is directed to a process of preparing montelukast or a salt thereof with minimal amounts of impurities, such as a dehydration impurity (compound (VI)) or a cyclic ether impurity (compound (VIII)).

PROCESS FOR PREPARING MONTELUKAST SODIUM CONTAINING CONTROLLED LEVELS OF IMPURITIES

The present invention is directed to a process of preparing montelukast or a salt thereof with minimal amounts of impurities, such as a dehydration impurity (compound (VI)) or a cyclic ether impurity (compound (VIII)).

PREPARATION OF MONTELUKAST

A process for preparing amorphous montelukast sodium comprises removing solvent from a solution comprising montelukast sodium using agitated thin film drying.